WO2020017828A1 - Comprimé comprenant une structure de contrôle de la libération de médicaments et procédé de fabrication de comprimé faisant appel à la technologie d'impression 3d - Google Patents

Comprimé comprenant une structure de contrôle de la libération de médicaments et procédé de fabrication de comprimé faisant appel à la technologie d'impression 3d Download PDF

Info

Publication number
WO2020017828A1
WO2020017828A1 PCT/KR2019/008585 KR2019008585W WO2020017828A1 WO 2020017828 A1 WO2020017828 A1 WO 2020017828A1 KR 2019008585 W KR2019008585 W KR 2019008585W WO 2020017828 A1 WO2020017828 A1 WO 2020017828A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
tablet
passage
reservoir
main
Prior art date
Application number
PCT/KR2019/008585
Other languages
English (en)
Korean (ko)
Inventor
김상욱
김영래
이홍기
김정태
박천웅
강지현
김동욱
Original Assignee
주식회사 코아팜바이오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 코아팜바이오 filed Critical 주식회사 코아팜바이오
Publication of WO2020017828A1 publication Critical patent/WO2020017828A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
    • B29C64/30—Auxiliary operations or equipment
    • B29C64/386—Data acquisition or data processing for additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y50/00—Data acquisition or data processing for additive manufacturing

Definitions

  • the present invention relates to tablets comprising drug release control structures and to methods of making such tablets using 3D printing techniques. More specifically, the present invention relates to tablets capable of controlling the inflow and release of drugs through structures having primary and secondary drug pathways, and methods of making such tablets using 3D printing techniques.
  • Drug release control technology has played a key role in improving drug treatment and lowering toxicity over the past 30 years.
  • advantages such as effective maintenance of blood concentration, constant treatment effect, prolongation of action time, reduction of administration frequency, minimization of side effects, improvement of patient medication compliance, and the like.
  • the drug release control technology uses a method of controlling the rate of water penetration of the tablet and controlling the diffusion of the drug in the tablet by using an additive that can control drug release, tablet coating, granulation, and application of osmotic technology. Doing.
  • Korean Patent Laid-Open Publication No. 10-2007-0094009 discloses a matrix tablet obtained by directly tableting a mixture of a drug and a polymer in order to achieve controlled release of the active ingredient.
  • control of release of various drugs is difficult, control of drug release is still difficult as tablets are broken down in the human body, and product quality is uneven and cost increases due to complicated manufacturing processes. There is.
  • a tablet comprising a drug release controlling structure comprises a tablet body; A drug reservoir disposed inside the tablet body, the drug reservoir being a space surrounded by the tablet body; A main drug passage, one end of which is connected to the drug reservoir and the other end of which is connected to the outside of the tablet body to provide a passage communicating the drug reservoir and the outside of the tablet body; And a secondary drug passage, one end of which is connected to the drug reservoir and the other end of which is connected to the outside of the tablet body, to provide a passage communicating the drug reservoir and the outside of the tablet body.
  • the flow rate of the fluid is less than the flow rate of the fluid flowing through the main drug passage.
  • the release rate of the drug located in the drug reservoir may be controlled by the size of the cross-sectional area of the main drug passage.
  • the tablet body is disposed below the intermediate layer, the intermediate layer forming the drug reservoir, the main drug passage and the secondary drug passage, and the drug reservoir, the main drug It may include a lower layer forming the passage and the lower surface of the secondary drug passage, and an upper layer disposed on the intermediate layer, and the upper layer forming the upper surface of the drug reservoir, the main drug passage and the secondary drug passage.
  • the cross-sectional area of the secondary drug passage may be smaller than that of the main drug passage.
  • one or more primary and secondary drug passages connected to the drug reservoir may be formed, respectively.
  • one or more drug reservoirs may be formed, and each drug reservoir is connected to one or more primary drug channels and secondary drug channels, respectively.
  • the sub-drug passage may include one or more bends or uneven parts to change the direction in which the fluid flows at least once.
  • Tablets according to the invention can be prepared using a 3D printer.
  • a method of manufacturing a tablet using 3D printing includes: forming a lower layer (a); On top of the lower layer, a drug reservoir, a main drug passage, one end of which is connected to the drug reservoir and the other end of which is connected to the outer side of the intermediate layer, and an auxiliary main drug passage, of which one end is connected to the drug reservoir and the other end is connected to the outer side of the intermediate layer. (B) forming an intermediate layer by forming a film; (C) forming an upper layer to cover the top of the intermediate layer.
  • the flow rate of the fluid flowing through the secondary drug passage is less than the flow rate of the fluid flowing through the main drug passage.
  • the method of manufacturing a tablet using the 3D printer according to the present invention may further include the step (d) of injecting the drug into the drug reservoir through the main drug passage or the secondary drug passage.
  • a design drawing of a tablet to be manufactured in a 3D printer when inputting or selecting a design drawing of a tablet to be manufactured in a 3D printer, information on the cross-sectional area of a predetermined main drug passage and / or a secondary drug passage (ie , Width and height information) can be entered or selected.
  • Tablets comprising the drug release control structure of the present invention, because the drug release control is possible, it is possible to provide a customized tablet according to the disease and individual characteristics.
  • a tablet containing a drug release control structure using 3D printing technology, it is possible to form a drug release port having a complex structure, to reduce the cost through a simple process, and to reduce the quality difference between the manufactured tablets. Can be reduced.
  • FIG 1 and 2 are perspective views of tablets made in accordance with one embodiment of the present invention.
  • FIG. 3-6 are cross-sectional views of an interlayer of a tablet made in accordance with various embodiments of the present invention.
  • FIG. 10 is a reference diagram for explaining the manufacturing conditions in the embodiment of the present invention.
  • 11 is a photograph showing the degree of dissolution during the dissolution test.
  • FIG. 1 and 2 are a perspective view of a tablet 100 according to an embodiment of the present invention
  • Figure 1 is a perspective view from the side of the secondary drug passage 140 is formed
  • Figure 2 is a side from the main drug passage 130 is formed This is a perspective view.
  • Tablet 100 including a drug release control structure according to an embodiment of the present invention, the tablet body 110; A drug reservoir 120 disposed inside the tablet body 110 and surrounded by the tablet body 110; One end is connected to the drug reservoir 120 and the other end is connected to the outside of the tablet body 110 to provide a passage for communicating the outside of the drug reservoir 120 and the tablet body 110. 130; And an auxiliary drug having one end connected to the drug reservoir 120 and the other end connected to the outside of the tablet body 110 to provide a passage communicating the outside of the drug reservoir 120 and the tablet body 110. Passage 140.
  • the flow rate of the fluid flowing through the secondary drug passage 140 is less than the flow rate of the fluid flowing through the main drug passage 130.
  • the tablet body 110 may generally be made of a material used to form the tablet 100.
  • the material of the tablet body 110 is not particularly limited, but may include a biodegradable plastic such as polylactic acid (PLA). It may also comprise a carbohydrate-like material selected from the group of sugars, starches and modified starches such as lactose, dextrose, fructose, sucrose, maltodextrin, cyclodextrin and corn syrup. In addition, it may include disintegrating polymers or polymers for extended release, which are generally used in the refining field.
  • the disintegratable polymer may be polyvinylpyrrolidone derivatives, starch derivatives, calcium salts, magnesium salts, carboxymethylcellulose derivatives, and mixtures thereof.
  • the sustained release polymer may be gum, galactomannan, glucomannan, succinoglycan, scleroglucan, and mixtures thereof.
  • the drug reservoir 120 is a space that stores a drug inside the tablet 100.
  • the drug refers to a substance having an active ingredient, and includes not only medicines but also extracts of health supplements.
  • the shape of the drug reservoir 120 may be any shape, but is preferably a spherical or cylindrical shape.
  • the volume of the reservoir 120 may be 10 to 20% with respect to the volume of the tablet 100, but may vary depending on the release rate and dosage required in consideration of the type of drug and the characteristics of the patient.
  • the secondary drug passage 140 has one end connected with the drug reservoir 120 and the other end connected with the outside of the tablet body 110 to communicate with the drug reservoir 120 and the outside of the tablet body 110.
  • the secondary drug passage 140 may serve as a passage for injecting a drug into the drug reservoir 120 disposed inside the tablet 100.
  • Drugs in liquid, solid or semisolid (eg hydrogel or gel, etc.) form may be injected into the drug reservoir.
  • Drugs capable of flow, such as liquids or semisolids can be injected into the drug reservoir via a syringe or nozzle.
  • the drug in solid form may be injected into the drug reservoir while dispersed in a dispersion medium such as liquid or semisolid, or directly in the form of a powder or granules.
  • the secondary drug passage 140 may be formed to have a constant cross section from the reservoir 120 to the outside of the tablet body 110.
  • the side drug passage 140 may be formed to have a plurality of bends from the reservoir 120 to the outside of the tablet body 110 to impart greater resistance to the fluid flowing through the side drug passage 140 (FIG. 6, 140).
  • the main drug passage 130 has one end connected to the drug reservoir 120 and the other end connected to the outside of the tablet body 110 to communicate the drug reservoir 120 and the outside of the tablet body 110.
  • the main drug passage 130 is disposed to be spaced apart from the secondary drug passage 140, the main drug passage 130 and the secondary drug passage 140 is not in communication with each other.
  • the main drug passage 130 serves as a passage through which drugs stored in the drug reservoir 120 are released to the outside.
  • the shape or length and cross-sectional area (eg, width and height) of the cross section of the main drug passage 130 By controlling the shape or length and cross-sectional area (eg, width and height) of the cross section of the main drug passage 130, the release rate of the drug stored in the drug reservoir 120 may be controlled. This allows for a suitable release rate to be implemented in consideration of the type of drug, type of disease and patient characteristics.
  • the tablet 100 may be manufactured using 3D printing technology.
  • the main drug passage 130 has a predetermined height (for example, within a range of 1 to 3 mm). It is preferable to determine so as to be either value). Therefore, in the tablet 100 according to the present embodiment, the cross section of the main drug passage 130 may be rectangular, and the rate of release of the drug contained in the reservoir 120 may be controlled by adjusting the width of the cross section. have.
  • Drugs stored in the reservoir 120 may move through the primary drug pathway 130 as well as the secondary drug pathway 140. At this time, if the drug exits a large amount out of the tablet body 110 through the secondary drug passage 140, even if the structure of the main drug passage 130 is changed, it is difficult to accurately control the release rate of the drug. In order to solve this problem, the flow rate of the fluid flowing into the secondary drug passage 140 can be designed so that the main discharge flow by the main drug passage 130 appears.
  • the flow rate of the fluid flowing through the secondary drug passage 140 is the main drug passage 130 It is designed to be less than the flow rate of the fluid flowing through it.
  • the flow rate refers to the amount of fluid passing through the cross section per unit time.
  • the flow rate can be represented by the following equation:
  • each passage 130, 140 may be controlled.
  • the secondary drug passage 130 is designed to have a plurality of bends, or a method of forming irregularities in the secondary drug passage (130).
  • the tablet 100 may be manufactured using 3D printing technology and the height of the main drug passage 130 and the sub drug passage 140 may be determined to a specific height.
  • the tablet 100 according to the embodiment of the present invention is formed by making the width of the secondary drug passage 140 smaller than the width of the main drug passage 130 by the fluid flowing through the secondary drug passage 140 The flow rate of may be smaller than the flow rate of the fluid flowing through the main drug passage 130.
  • Tablet body 110 of the present embodiment can be manufactured using 3D printing technology.
  • the tablet body 110 is divided into an intermediate layer in which complex structures such as the drug reservoir 120, the main drug passage 130, and the secondary drug passage 140 are formed therein, and an upper layer and a lower layer covering the upper and lower portions of the intermediate layer.
  • An intermediate layer in which complex structures such as the drug reservoir 120, the main drug passage 130, and the secondary drug passage 140 are formed therein, and an upper layer and a lower layer covering the upper and lower portions of the intermediate layer.
  • an upper layer and a lower layer covering the upper and lower portions of the intermediate layer.
  • the lower layer, the middle layer, and the upper layer are illustrated for convenience of description, but when manufactured by a 3D printer, the lower layer, the middle layer, and the upper layer are integrally formed so that the lower layer, the middle layer, and the upper layer may not be visually distinguished. Can be.
  • 3 to 6 are interlayer cross-sectional views illustrating the internal structure of tablets 100 according to embodiments 2 to 5 of the present invention, respectively.
  • the drug reservoir 120 may be formed to be deflected on one side of the tablet body 110, and the secondary drug passage 140 may have a smaller width than the main drug passage 130.
  • two or more primary drug channels 130a and 130b and secondary drug channels 140a and 140b may be formed with respect to one drug reservoir 120.
  • the number of the primary drug passages 130a and 130b and the number of the secondary drug passages 140a and 140b are not necessarily the same, but may be determined to implement the required release rate.
  • the secondary drug passage may have a width smaller than that of the main drug passage and form a long length, thereby reducing the flow rate flowing through the secondary drug passage.
  • two or more drug reservoirs 120a and 120b may be formed. It may include a main drug passage (130a, 130b) and side drug passages (140a, 140b) connected to each of the drug reservoir (120a, 120b). Each of the drug reservoirs 120a and 120b may store different kinds of drugs. In addition, the shape of the main drug passage (130a, 130b) and the side drug passages (140a, 140b) connected to the respective drug reservoir (120a, 120b) is different depending on the type of drug stored in the drug reservoir (120a, 120b) Can be formed. Through this structure, the drug release rate can be controlled differently according to the drug.
  • the auxiliary drug passage 140 may include a bent portion to change the flow direction of the fluid at least once when the fluid flows from the outside of the tablet body 110 to the reservoir 120. have. Through this structure, it is possible to increase the resistance to the flow of the fluid of the secondary drug passage 140.
  • the tablet 100 including the drug release control structure of the present invention is a member (eg, the main drug passage 130 and the secondary drug passage 140 is in communication with the outside of the tablet body 110 to block the exposed portion (eg, Tablet coating layer or a plug made of a biodegradable or water-soluble polymer) may be further included. This may be controlled so that the drug in the reservoir 120 is released to the outside only under certain conditions.
  • a member eg, the main drug passage 130 and the secondary drug passage 140 is in communication with the outside of the tablet body 110 to block the exposed portion (eg, Tablet coating layer or a plug made of a biodegradable or water-soluble polymer) may be further included. This may be controlled so that the drug in the reservoir 120 is released to the outside only under certain conditions.
  • Tablets of the present invention can be prepared using 3D printing technology.
  • Tablet 100 comprising a drug release control structure according to an embodiment of the present invention includes a complex structure, such as drug reservoir 120, the main drug passage 130 and the secondary drug passage 140 therein, the main drug
  • the release rate of the drug may be controlled according to the shape of the passage 130. It is desirable to use 3D printing technology to provide tablets 100 having such complex and precise structures.
  • a design drawing of a tablet 100 to be manufactured is input or selected in the 3D printer.
  • the plate-shaped lower layer 110a is formed using the 3D printer, and the drug reservoir 120 and one end of the lower layer 110a are connected to the drug reservoir 120 and the other end of the intermediate layer 110b.
  • the intermediate drug layer 130b is formed such that the main drug passage 130 connected to the outer side, and the secondary drug passage 130 connected to the drug reservoir 120 and one end thereof connected to the outer side of the intermediate layer 110b are formed.
  • a plate-shaped upper body 110c is formed to cover the middle layer 110b and the upper portion of the drug reservoir 120, the main drug passage 130, and the secondary drug passage 140.
  • the tablet 100 is manufactured such that the flow rate of the fluid flowing through the secondary drug passage 140 is smaller than the flow rate of the fluid flowing through the main drug passage 130.
  • the 3D printer is not particularly limited as long as it can form the molded object using a material suitable for the tablet 100 such as biodegradable plastic.
  • a FDM (Fused Deposition Modeling) 3D printer using a PLA filament, which is one of bioplastics, to manufacture a sculpture is used.
  • the raw material supplied for the production of sculptures in the 3D printer is not particularly limited as a material suitable for the tablet 100.
  • the raw material may include a bio plastic such as PLA. It may also include materials of carbohydrates selected from the group of sugars, starches and modified starches such as lactose, dextrose, fructose, sucrose, maltodextrin, cyclodextrin and corn syrup.
  • it may include disintegrating polymers or polymers for extended release, which are generally used in the field of tablets 100.
  • the disintegratable polymers may be polyvinylpyrrolidone derivatives, starch derivatives, calcium and magnesium salts, and carboxymethylcellulose derivatives, and mixtures thereof.
  • the sustained release polymer may be gum, galactomannan, glucomannan, succinoglycan and scleroglucan, and mixtures thereof.
  • the raw material may be supplied in powder form or filament shape.
  • the drawing may be a customized three-dimensional drawing of the tablet 100 designed in consideration of a drug, a disease to be treated or a patient.
  • the tablet 100 since the tablet 100 is manufactured using a 3D printer, the tablet 100 may be manufactured by applying different drawings according to the tablet 100.
  • the size (ie, width or width and height) of the cross-sectional area of the main drug passage 130 and / or of the secondary drug passage 140 can be determined.
  • the height of the main drug passage 130 is a specified height, preferably May be set to any value in the range of 1 to 3 mm.
  • the tablet 100 according to the present invention may be controlled by the release rate of the drug stored in the reservoir 120 by adjusting the width of the main drug passage 130.
  • Tablets 100 may be prepared to implement drug release rates designed to be suitable for the application.
  • the step of manufacturing the tablet 100 may include manufacturing a portion (middle layer) including the drug reservoir 120, the main drug passage 130, and the secondary drug passage 140 in the body of the tablet 100. Step and other parts (ie, bottom layer and top layer) can be divided into steps.
  • the lower layer 110a and the upper layer 110c do not include a complicated structure, and serve to wrap the structure of the drug reservoir 120 and the like on the upper and lower sides, and thus may be a plate-shaped that can be easily formed through a 3D printer. have.
  • the intermediate layer 110b includes a complicated structure and is suitable for manufacturing using a 3D printer.
  • the 3D printer is an FDM method
  • the nozzle may be moved in three axes to produce a shape in which the drug reservoir 120 is provided.
  • the upper body 110c having a plate shape is formed to cover the middle layer 110b and the upper portion of the drug reservoir 120, the main drug passage 130, and the secondary drug passage 140.
  • a solid line is illustrated to distinguish the lower layer, the middle layer, and the upper layer for convenience of description, but since the lower layer, the middle layer, and the upper layer are integrally formed, the solid line separating the lower layer, the middle layer, and the upper layer does not actually exist. It is shown for convenience.
  • the method may further include injecting a drug into the drug reservoir 120 through the secondary drug passage 140.
  • the tablets formed a drug reservoir, a primary drug channel and a secondary drug channel according to the shape of FIG. 10.
  • the total height of the tablet is 6 mm
  • the height of the drug reservoir, the main drug passage and the side drug passage is 2 mm, and formed to cover the top and bottom layers of 2 mm thickness on the top and bottom, respectively.
  • the tablets had an elliptical columnar shape, the length f of the major axis of the oval was 20 mm, the length g of the minor axis was 12 mm, and the height of the tablet was 6 mm.
  • the drug reservoir was made into a cylindrical shape having a diameter (c) of 10 mm, and formed the main drug passage and the secondary drug passage in the major axis direction in the elliptical tablet body.
  • the length (d) of the main drug channel was 8 mm
  • the width (a) was 1 mm
  • the length (e) of the drug delivery channel was 2 mm
  • the width (b) was 0.7 mm.
  • the tablets were prepared using a FDM 3D printer (ECO-premium model, E-ace, South Korea) as a raw material of PLA filament.
  • the hydrogel to which the methylene blue pigment was added was filled to the reservoir of the tablet thus prepared through the secondary drug channel.
  • Example 7 The same procedure as in Example 7 was conducted except that the width (a) of the main drug passage was 2 mm.
  • Example 7 The same procedure as in Example 7 was conducted except that the width (a) of the main drug passage was 3 mm.
  • Table 1 shows the results of this experimental example
  • Figure 11 is a photograph of the degree of dissolution over time for the tablet of Example 8.
  • Example 7 Example 8
  • Example 9 Example 10 30 min elution rate in pH 6.8 buffer 33.5 47.9 73.6 30.5
  • Tablets comprising the drug release control structure of the present invention, because the drug release control is possible, it is possible to provide a customized tablet according to the disease and individual characteristics.
  • a tablet containing a drug release control structure using 3D printing technology, it is possible to form a drug release port having a complex structure, to reduce the cost through a simple process, and to reduce the quality difference between the manufactured tablets. Can be reduced.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Manufacturing & Machinery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Mechanical Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un comprimé comprenant une structure de contrôle de la libération de médicaments et un procédé de fabrication de comprimé faisant appel à la technologie d'impression 3D.
PCT/KR2019/008585 2018-07-20 2019-07-11 Comprimé comprenant une structure de contrôle de la libération de médicaments et procédé de fabrication de comprimé faisant appel à la technologie d'impression 3d WO2020017828A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2018-0084670 2018-07-20
KR1020180084670A KR20200013170A (ko) 2018-07-20 2018-07-20 약물 방출 제어 구조를 포함하는 정제 및 3d 프린트 기술을 이용한 정제 제조방법

Publications (1)

Publication Number Publication Date
WO2020017828A1 true WO2020017828A1 (fr) 2020-01-23

Family

ID=69165090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/008585 WO2020017828A1 (fr) 2018-07-20 2019-07-11 Comprimé comprenant une structure de contrôle de la libération de médicaments et procédé de fabrication de comprimé faisant appel à la technologie d'impression 3d

Country Status (2)

Country Link
KR (1) KR20200013170A (fr)
WO (1) WO2020017828A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021249286A1 (fr) * 2020-06-11 2021-12-16 许新朋 Nouvelle formule de médicament destiné à l'immunothérapie et structure de comprimé associée
CN114248434A (zh) * 2021-12-22 2022-03-29 广东药科大学 一种释放时间可控制的3d打印制药方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743248A (en) * 1986-08-11 1988-05-10 Alza Corporation Dosage form for delivering acid sensitive beneficial agent
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
US20020071866A1 (en) * 1999-12-16 2002-06-13 Geerke Johan H. Dosage forms having a barrier layer to laser ablation
WO2017072536A1 (fr) * 2015-10-29 2017-05-04 University Of Central Lancashire Formes solides et leurs procédés de préparation
US20170232667A1 (en) * 2012-10-04 2017-08-17 Robert W. Adams Process for making controlled release medical implant and non-implant products

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491665A1 (fr) 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743248A (en) * 1986-08-11 1988-05-10 Alza Corporation Dosage form for delivering acid sensitive beneficial agent
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
US20020071866A1 (en) * 1999-12-16 2002-06-13 Geerke Johan H. Dosage forms having a barrier layer to laser ablation
US20170232667A1 (en) * 2012-10-04 2017-08-17 Robert W. Adams Process for making controlled release medical implant and non-implant products
WO2017072536A1 (fr) * 2015-10-29 2017-05-04 University Of Central Lancashire Formes solides et leurs procédés de préparation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021249286A1 (fr) * 2020-06-11 2021-12-16 许新朋 Nouvelle formule de médicament destiné à l'immunothérapie et structure de comprimé associée
CN114248434A (zh) * 2021-12-22 2022-03-29 广东药科大学 一种释放时间可控制的3d打印制药方法

Also Published As

Publication number Publication date
KR20200013170A (ko) 2020-02-06

Similar Documents

Publication Publication Date Title
WO2020017828A1 (fr) Comprimé comprenant une structure de contrôle de la libération de médicaments et procédé de fabrication de comprimé faisant appel à la technologie d'impression 3d
US6610323B1 (en) Oral pharmaceutical pulsed release dosage form
AU712325B2 (en) Multiple unit effervescent dosage forms comprising protonpump inhibitor
US5026560A (en) Spherical granules having core and their production
CA2599340C (fr) Procede de fabrication de granules
KR100396171B1 (ko) 염산 파수딜의 경구 서방성 제제
MX2008010877A (es) Tabletas de liberacion prolongada de succinato de metroprolol y metodos para su preparacion.
DE3228595A1 (de) System zur parenteralen verabreichung eines wirkstoffs
EP2995299A1 (fr) Particule revêtue d'un film polymère fonctionnel ayant une grande teneur en médicament, comprimé la contenant, et procédés de production associés
KR960006062B1 (ko) 딜티아젬(diltiazem) 공급용의 제형(dosage form)
EP1830849B1 (fr) Formes galeniques a liberation rapide pour antibiotiques
US3044938A (en) Sustained action pharmaceutical tablets
US8299052B2 (en) Pharmaceutical compositions and methods for improved bacterial eradication
CN111110649A (zh) 一种通用的新型儿童药物制剂掩味颗粒及其制备方法
CN107308127A (zh) 双氯芬酸钠多单元缓释微丸片
KR20160076928A (ko) 푸마르산 에스테르를 함유하는 미니-정제 형태의 약제학적 제제
WO2019160243A1 (fr) Composition pharmaceutique à libération prolongée contenant du lacosamide
Gandhi et al. Recent trends in sustained release drug delivery system
KR20210073285A (ko) 프로톤펌프억제제 및 모사프리드를 포함하는 유핵정 제제
KR20050061647A (ko) 소화성 궤양 치료를 위한 프로톤펌프 저해제와클래리스로마이신을 함유하는 이중 펠렛 제제 및 그의제조방법
EP3337462B1 (fr) Mini-comprimés de mélatonine et leur procédé de fabrication
KR102647890B1 (ko) 콜린 알포세레이트 함유 약제학적 조성물
TWM592763U (zh) 藥錠結構
JP2010537759A (ja) 有効成分の経口投与装置
CA2635378C (fr) Compositions pharmaceutiques et methodes pour eradication bacterienne amelioree

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19837844

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19837844

Country of ref document: EP

Kind code of ref document: A1